George Yancopoulos - Dec 22, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President and Chief Scientific, Director
Signature
/s/**George D. Yancopoulos
Stock symbol
REGN
Transactions as of
Dec 22, 2021
Transactions value $
-$91,395,761
Form type
4
Date filed
12/23/2021, 03:29 PM
Previous filing
Aug 17, 2021
Next filing
Feb 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $42.8M +239K +26.94% $179.13 1.13M Dec 22, 2021 Direct
transaction REGN Common Stock Tax liability -$97.6M -160K -14.2% $610.04 967K Dec 22, 2021 Direct
transaction REGN Common Stock Options Exercise $55M +203K +21.02% $270.43 1.17M Dec 22, 2021 Direct
transaction REGN Common Stock Tax liability -$91.6M -150K -12.84% $610.04 1.02M Dec 22, 2021 Direct
holding REGN Common Stock 5.85K Dec 22, 2021 By 401(k) Plan
holding REGN Common Stock 214K Dec 22, 2021 By Trust for Chldn. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -239K -100% $0.00* 0 Dec 22, 2021 Common Stock 239K $179.13 Direct F2
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -203K -100% $0.00* 0 Dec 22, 2021 Common Stock 203K $270.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As investment trustee of trusts for the benefit of the reporting person's children.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.